ALGS News and Press, Aligos Therapeutics Inc. From 04/04/22

Aligos Therapeutics (NASDAQ:ALGS +7.0%) said it had selected oral protease inhibitor ALG-097558 as its drug candidate for the treatment and prevention of COVID-19. The company said its drug ALG-097558 has shown superior potency compared to nirmatrelvir (PF-07321332) against SARS-CoV...

SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has selected ALG-...

Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...

Clinical-stage biotech, Aligos Therapeutics (NASDAQ:ALGS) announced on Tuesday that the company decided to discontinue the development of its chronic hepatitis B (CHB) candidate, ALG-020572 after a trial subject experienced a serious adverse event (SAE). Dosing of the first cohort of the tria...

Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accele...

Aligos Therapeutics press release (NASDAQ:ALGS): Q4 GAAP EPS of -$0.89 misses by $0.06. Q4 Cash , cash equivalents $205.8M For further details see: Aligos Therapeutics GAAP EPS of -$0.89 misses by $0.06

CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1b ASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1 st cohort fully enrolled siRNA (ALG-125755) progressing on track through Phase 1 enabling no...

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it will report the c...

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph...

Administration of single ascending doses up to 480 mg in healthy volunteers nearly complete First chronic hepatitis B patient dosed in initial cohort, each of which will be administered 7 subcutaneous doses over 29 days SOUTH SAN FRANCISCO, Calif., Jan. 26, 2022 (GLOBE NEW...